A recent post-mortem immunohistochemistry report of a case of TBK1 mutated patient established a classical ALS and type B TDP pathology without changes in TBK1 staining or interferon regulatory factor-3 (IRF3), a transcription factor that controls multiple IFN-inducing pathways related to inflammation and immunity. This evidence concerns the gene IRF3 and amyotrophic lateral sclerosis.